CTNM vs JNJ: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
JNJ is the larger of the two ($615.87B market cap): the incumbent the market prices for continued execution (21.83x forward earnings, beta 0.21). CTNM is the smaller challenger ($266.36M), priced similarly on forward earnings (-3.67x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
CTNM vs JNJ: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CTNM | JNJ | What it tells you |
|---|---|---|---|
| Market cap | $266.36M | $615.87B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -3.67 | 21.83 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.86 | 0.21 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 1% of range | 74% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.11 | 7.24 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how CTNM and JNJ affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CTNM and JNJ share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CTNM and JNJ exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Contineum Therapeutics (CTNM) do?
Contineum Therapeutics, formerly Pipeline Therapeutics, is a San Diego biotech that listed on the Nasdaq in April 2024 through an IPO priced at $16 a share that raised ~$110 million. It develops oral small-molecule drugs for fibrotic, inflammatory and neurological diseases, and it has no approved products. The lead program is PIPE-791, a once-daily oral antagonist of the LPA1 receptor, a lipid-signalling receptor tied to the scarring that drives IPF. PIPE-791 is in PROPEL-IPF, a global, randomized, placebo-controlled Phase 2 trial of ~324 patients whose primary endpoint is the change in forced vital capacity (FVC, how much air a patient can exhale) over 26 weeks. The second asset, PIPE-307, a selective M1 muscarinic receptor inhibitor, is licensed to Johnson & Johnson, which paid $50 million upfront in 2023, bought $25 million of stock, and owes up to ~$1.0 billion in milestones plus royalties if it succeeds. The company makes money today only from interest on its cash.
What does Johnson & Johnson (JNJ) do?
Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.
CTNM vs JNJ: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CTNM drivers: The PROPEL-IPF readout for PIPE-791; What admilparant means for the LPA1 class.
- JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is binary: if PROPEL-IPF does not show a meaningful FVC benefit, the stock has little to support it beyond cash, and that cash falls by roughly ~$60 million a year. For JNJ, j&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue.
CTNM or JNJ: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CTNM if you believe its drivers more; JNJ if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CTNM and JNJ guides.
CTNM vs JNJ: the full fundamentals
CTNM. Contineum has no sales and loses money, so price-to-earnings and price-to-sales ratios do not apply. The useful comparison is market value against cash. After the October 12 fall, the enterprise value (market value minus cash) is roughly ~$85 million to ~$100 million, and that is what the market assigns to PIPE-791, the J&J milestones and everything else combined. Price to book is ~1.3, which says the same thing. The next scheduled update is third-quarter results, which should show the cash balance and any word from J&J on PIPE-307.
JNJ. J&J's trailing P/E near 39 is inflated by a third quarter in which GAAP net income fell to about $210 million on items excluded from adjusted results; on forward estimates (about $11.71 of EPS for 2027) the multiple is near 22. That is a premium to where the stock traded early in 2026, after a roughly 24% year-to-date rise, and the dividend yield has compressed to about 2.1%. The market is paying for steady mid single-digit growth, high margins, strong cash generation and a raised 2026 outlook, still with some discount for litigation and patent-cliff overhangs; figures are approximate as of October 16, 2026.
Headline figures (approximate, October 2026): CTNM shows revenue (ttm) ~$0 (no product or collaboration revenue reported in 2026), net loss (q2 2026) ~$15.2 million (vs ~$16.0 million in Q2 2025), r&d expense (q2 2026) ~$12.7 million (down 10% year over year), cash and marketable securities ~$236.6 million (June 30, 2026); JNJ shows revenue (ttm) ~$99 billion, q3 2026 sales ~$25.4 billion (+~6% YoY), q3 2026 adjusted eps $2.59 (vs ~$2.52 est.), operating margin ~25%.
The bottom line: CTNM vs JNJ
CTNM and JNJ are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CTNM and JNJ exposure against your real portfolio. It is not an investment adviser.
Wondering how CTNM or JNJ fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Contineum Therapeutics with AI
Connect the broker you already use and ask Walnut's AI how CTNM fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between CTNM and JNJ?
+
Contineum Therapeutics, formerly Pipeline Therapeutics, is a San Diego biotech that listed on the Nasdaq in April 2024 through an IPO priced at $16 a share that raised ~$110 million. Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CTNM or JNJ the better stock?
+
Neither is universally better. JNJ is the larger incumbent; CTNM is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CTNM or JNJ?
+
On forward P/E (as of October 2026), CTNM trades at -3.67x and JNJ at 21.83x, so CTNM is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CTNM and JNJ?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CTNM vs JNJ?
+
CTNM: The central risk is binary: if PROPEL-IPF does not show a meaningful FVC benefit, the stock has little to support it beyond cash, and that cash falls by roughly ~$60 million a year. Even with positive data, admilparant is a Phase 3 asset backed by a large pharma company heading toward filings, so it would likely reach patients years before PIPE-791. The IPF market already includes Boehringer Ingelheim's Ofev (nintedanib), generic pirfenidone and Boehringer's newer nerandomilast, so a late entrant needs clear differentiation on efficacy, tolerability or convenience. PIPE-307 has now missed in two Phase 2 trials (multiple sclerosis in 2025 and depression in 2026), and J&J alone decides whether to continue, so the milestone stream could disappear. The research workforce cut and the departure of the chief scientific officer narrow the pipeline behind PIPE-791. The stock is small and highly sensitive to peer news, as the ~36% one-day fall on a competitor's trial showed, and any Phase 3 would almost certainly need new financing or a partner, which could dilute existing holders. JNJ: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. Drug pricing pressure, including US government negotiation of certain drug prices, can weigh on margins. The company also faces significant legal liability, most notably ongoing litigation related to talc-based products, which has created uncertainty and large potential settlements. MedTech competes in tough device markets and is exposed to hospital budgets and procedure volumes. Regulatory, clinical-trial, and product-safety risks are inherent to healthcare. International pricing pressure weighed on third-quarter 2026 results, and large items outside adjusted earnings cut GAAP net income to about $210 million that quarter. Growth is steady rather than rapid, yet after a roughly 34% one-year rise the stock trades near 22 times forward earnings, so valuation now leaves less cushion than it did when J&J traded in the mid-teens.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CTNM or JNJ; figures are approximate and dated (as of October 2026). Verify current data before investing.